The new AI-backed tool provides meal suggestions, ingredient substitutions, and meal planning guidance to help patients avoid their identified trigger foods while maintaining dietary variety. The system was developed in collaboration with dietitians from the University of Michigan. “Unlike broad elimination diets, inFoods IBS has the ability to identify select and specific IBS trigger foods, which makes compliance more achievable,” says Zack Irani, CEO of Biomerica, in a release. “The new AI-backed Trigger Food Navigator takes this one step further by guiding patients through everyday food choices and offering easy substitutions.”
Author: Abhay Panchal
London-based biotech startup BoobyBiome has raised €2.8M to transform infant gut health through the breast milk microbiome. Backed by top investors, the female-founded company is developing a patented storage device that preserves the natural microbiome in expressed milk and a live microbiome drop designed to support formula-fed, c-section, or preterm babies. With the world’s largest breast milk microbiome database behind them, the team is tackling rising childhood diseases linked to underdeveloped microbiomes. Could this be the breakthrough that redefines infant nutrition globally?
Locum tenens is often dismissed as a stopgap in medicine—but for some physicians, it’s a path back to purpose. In this reflection, a pediatrician shares how choosing locums unlocked financial freedom, community ties, and a renewed sense of why he became a doctor. From paying off $315K in debt to finding stability in supposed instability, the story challenges long-held assumptions. Could the “wanderer’s route” actually be the future antidote to burnout in medicine?
Early-onset gastrointestinal cancers are rising at alarming rates in adults under 50, yet most remain outside screening protocols—leaving vague symptoms overlooked and diagnoses delayed. Experts warn that lifestyle risks like obesity, diet, and inactivity combine with barriers such as insurance and access to fuel this trend. Emerging tools—from liquid biopsies to microRNA assays—hint at earlier detection, but they’re not ready for routine use. The unsettling question: how many lives are being lost simply because we’re looking too late?
Colonoscopy has long been the gold standard for colorectal cancer screening—but could AI and molecular testing change that? A new review explores how liquid biopsies, multi-omics, and AI-assisted colonoscopy are pushing the limits of early detection. While blood tests and stool assays promise convenience, their sensitivity lags behind. Meanwhile, cutting-edge tools like single-cell sequencing and spatial transcriptomics could rewrite how we diagnose and stratify risk. The big question: will these next-gen diagnostics ever truly rival colonoscopy’s dominance?
Gastroenterology is entering a new era where medicine isn’t just standardized—it’s personalized. Precision gastroenterology is using genetics, biomarkers, and digital diagnostics to tailor treatments for IBD, colorectal cancer, and liver disease. But the real transformation lies in blending science with empathy: care that considers not just a patient’s biology, but also their life goals and fears. Could this shift finally replace trial-and-error medicine with strategies as unique as each patient?
Colonoscopy is evolving beyond a diagnostic tool—mechanical add-ons like the Endocuff are quietly boosting adenoma detection rates, a key factor in preventing colorectal cancer. These innovations flatten folds, expose hidden polyps, and may even reduce the need for repeat procedures. Yet the gains are modest, and the next frontier—robotic systems—comes with steep costs and unanswered questions. Could simple mechanical tweaks prove more impactful than expensive high-tech solutions in reshaping colorectal cancer prevention?
Health insurance costs in America are about to soar in 2026—rising faster than inflation, and in some cases at levels not seen in 15 years. Employer plans will climb by 6.5%, but ACA exchange premiums may spike nearly 18%—with some families facing shocking fourfold increases if federal subsidies expire. Medicare isn’t spared either, with steep hikes expected in Parts B and D. As millions risk losing affordable coverage, one question looms: how much more can Americans really bear?
Guardant Health is taking its FDA-approved Shield™ blood test for colorectal cancer into senior living communities through a new partnership with LabFlorida. Instead of invasive colonoscopies or stool kits, residents can now be screened with a simple blood draw—making early detection far more accessible for a population at highest risk. With millions of seniors still missing routine screenings, will this move redefine how preventive cancer care is delivered to aging Americans?
Two new studies in Clinical Gastroenterology and Hepatology and Gastroenterology reveal just how powerfully the gut-brain connection shapes our eating habits. From stress and income to sensory food fears, the findings show that biology and life circumstances intertwine in surprising ways—sometimes driving people toward high-calorie foods, other times pushing them to avoid eating altogether. The research raises a big question: could personalized digestive care finally hinge on treating both the mind and the gut together?